| Predicted Trait | |
| Reported Trait | Coronary artery disease |
| Mapped Trait(s) | coronary artery disease (EFO_0000378) |
| Score Construction | |
| PGS Name | GRS_CAD |
| Variants | |
| Original Genome Build | NR |
| Number of Variants | 192 |
| Development Method | |
| Name | Genome-wide significant associations |
| Parameters | FDR < 5%, r2 < 0.20 |
| PGS Source | |
| PGS Catalog Publication (PGP) ID | PGP000009 |
| Citation (link to publication) | Paquette M et al. J Clin Lipidol (2017) |
| Study Identifiers | Sample Numbers | Sample Ancestry |
|---|---|---|
| GWAS Catalog: GCST003116 EuropePMC: 26343387 |
11,323 individuals | East Asian |
| GWAS Catalog: GCST003116 EuropePMC: 26343387 |
25,557 individuals | South Asian |
| GWAS Catalog: GCST003116 EuropePMC: 26343387 |
2,268 individuals | Greater Middle Eastern (Middle Eastern, North African or Persian) |
| GWAS Catalog: GCST003116 EuropePMC: 26343387 |
4,095 individuals | Hispanic or Latin American |
| GWAS Catalog: GCST003116 EuropePMC: 26343387 |
141,217 individuals | European |
| GWAS Catalog: GCST003116 EuropePMC: 26343387 |
3,139 individuals | African American or Afro-Caribbean |
Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.
|
PGS Performance Metric ID (PPM ID) |
PGS Sample Set ID (PSS ID) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
PGS Classification Metrics | Other Metrics | Covariates Included in the Model | PGS Performance: Other Relevant Information |
|---|---|---|---|---|---|---|---|---|
| PPM000039 | PSS000024 | PGP000009 Paquette M et al. (2017) |
Reported Trait: Coronary artery disease in familial hypercholesterolemia patients | OR: 1.8[1.14, 2.85] | — | — | age, gender, prior statin use, smoking, diabetes, hypertension, BMI, LDL-C, HDL-C, TGs, Lp(a), and type of LDLR mutation | Performance metrics are from Model 2 (adjusted for cardiovascular risk factors) |
| PPM000038 | PSS000023 | PGP000009 Paquette M et al. (2017) |
Reported Trait: Coronary artery disease in familial hypercholesterolemia patients | OR: 1.66[1.06, 2.62] | — | — | age, gender, prior statin use, smoking, diabetes, hypertension, BMI, LDL-C, HDL-C, TGs, Lp(a), and type of LDLR mutation | Performance metrics are from Model 2 (adjusted for cardiovascular risk factors) |
|
PGS Sample Set ID (PSS ID) |
Detailed Phenotype Description | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
|---|---|---|---|---|---|---|---|---|
| PSS000023 | CAD case endpoints were defined as: angina, myocardial infarction, coronary angioplasty, and coronary bypass surgery. Participants are described as Caucasian with diagnosed Familial hypercholesterolemia(FH; Dutch Lipid Criteria score >= 3 [possible, probable, or definite FH]) and carriers of classical French Canadian mutations in the LDLR gene including del .15 kb of the promoter and exon 1, del .5 kb of exons 2 and 3, W66G (exon 3), E207K (exon 4), Y468X (exon 10), and C646Y (exon 14). | — | [ ,
0.43 % Male samples |
— | European | CNMA | Nutrition, Metabolism and Atherosclerosis Clinic (CNMA) of Institut de recherches cliniques de Montréal | |
| PSS000024 | Cerebrovascular disease (CVD) case endpoints were defined as: transient ischemic attack, stroke, and carotid endarterectomy. Participants are described as Caucasian with diagnosed Familial hypercholesterolemia(FH; Dutch Lipid Criteria score >= 3 [possible, probable, or definite FH]) and carriers of classical French Canadian mutations in the LDLR gene including del .15 kb of the promoter and exon 1, del .5 kb of exons 2 and 3, W66G (exon 3), E207K (exon 4), Y468X (exon 10), and C646Y (exon 14). | — | [ ,
0.43 % Male samples |
— | European | — | CNMA | Nutrition, Metabolism and Atherosclerosis Clinic (CNMA) of Institut de recherches cliniques de Montréal |